Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 232 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: IOP Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy

NCT01345448
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine, Placebo Lotion
Drug
Lead sponsor
Nanduri, Padma, M.D., FACS
Individual
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Visalia, California
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Phase 4 Interventional

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

NCT00300079
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
brinzolamide 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 7, 2026, 10:05 AM EDT
Not listed Phase 3 Interventional

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
Drug
Lead sponsor
TearClear Corp
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Phase 3 Interventional

SOLX Titanium Sapphire Laser for Trabeculoplasty

NCT00145535
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT)
Device
Lead sponsor
SOLX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
Petaluma, California • Tampa, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Sep 7, 2026, 10:05 AM EDT
Terminated Not applicable Interventional Results available

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

NCT01828255
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG) Patient
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
40 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 7, 2026, 10:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Observational Study of How Patients Take Eye Drops

NCT00750646
View directory record Official record
Conditions
Glaucoma
Interventions
MEMS cap
Device
Lead sponsor
Robin, Alan L., M.D.
Individual
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Not applicable Interventional

Effect of Intra-subject Phaco/Trabectome vs. Phaco/Kahook Dual Blade on Intraocular Pressure

NCT03894631
View directory record Official record
Conditions
Glaucoma
Interventions
KDB/Phacoemulsification, Trabectome/Phacoemulsification
Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 95 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 7, 2026, 10:05 AM EDT
Completed No phase listed Observational

Survey of Patients Taking IOP-Lowering Eye Drops

NCT02384772
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Survey
Other
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 7, 2026, 10:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Functional and Structural Imaging for Glaucoma

NCT01957267
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 85 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

NCT00047528
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Alcon Investigational Agent
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Phase 4 Interventional

Phase 4 IOP Signals Associated With ILUVIEN®

NCT02424019
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
ILUVIEN 0.19 MG
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 7, 2026, 10:05 AM EDT
Completed No phase listed Observational

Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

NCT01042665
View directory record Official record
Conditions
Glaucoma
Interventions
latanoprost 0.005%, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Palm Beach Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Sep 7, 2026, 10:05 AM EDT
Not listed Phase 2 Interventional

A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

NCT02174991
View directory record Official record
Conditions
Glaucoma
Interventions
Rho-Kinase Inhibitor (AR-12286)
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

Next Generation Rocklatan

NCT06441643
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Not applicable Interventional

Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy

NCT00695747
View directory record Official record
Conditions
Glaucoma, Cataracts
Interventions
2 Site procedure- Phacoemulsification/IOL and Trabeculectomy
Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
Not listed
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

iCare IC1000 Alignment Study

NCT07022054
View directory record Official record
Conditions
Intraocular Pressure
Interventions
iCare IC1000 measurement
Device
Lead sponsor
Icare Finland Oy
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lake Worth, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT01687426
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
Brimonidine Tartrate 0.025%, Vehicle
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Not applicable Interventional Results available

iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery

NCT01786954
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Icare rebound tonometry, Tonopen applanation, Goldmann applanation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 7, 2026, 10:05 AM EDT
Not listed Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT06383273
View directory record Official record
Conditions
Cataract
Interventions
MELT-300 sublingual tablet, Midalozam sublingual tablet, Placebo sublingual tablet
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Chico, California • Grand Junction, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tonometry Precision and Accuracy During PROSE Scleral Lens Wear: A Pilot Study

NCT04308941
View directory record Official record
Conditions
Intraocular Pressure and PROSE Lens
Interventions
Intraocular pressure
Diagnostic Test
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 7, 2026, 10:05 AM EDT
Recruiting Not applicable Interventional

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

NCT05924477
View directory record Official record
Conditions
Glaucoma
Interventions
Sulcus tube placement, Anterior chamber (AC) tube placement
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
San Francisco, California • Walnut Creek, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 7, 2026, 10:05 AM EDT
Completed Not applicable Interventional Results available

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

NCT01539239
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Hydrus Aqueous Implant, Cataract surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 7, 2026, 10:05 AM EDT